IMMUNE PHARMACEUTICALS INC
IMNP evidence brief
What we can confirm
- BioSniper Score:
- 7.9 / 10
- Lead Asset:
- bertilimumab (Phase 2)
What it means
What to watch
Prepared research question
What matters most for IMNP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
bertilimumab (Phase 2)
Next Catalyst
—
Tracking 4 pipeline candidates · 7 clinical trials for IMMUNE PHARMACEUTICALS INC.
Run IMMUNE PHARMACEUTICALS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available IMMUNE PHARMACEUTICALS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 3
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Frequently asked questions
What is IMMUNE PHARMACEUTICALS INC's lead drug candidate?
IMMUNE PHARMACEUTICALS INC's most advanced tracked candidate is bertilimumab (Phase 2) for Ulcerative colitis.
Who is the CEO of IMMUNE PHARMACEUTICALS INC?
Anthony Fiorino Anthony is the chief executive officer of IMMUNE PHARMACEUTICALS INC (IMNP).
What therapeutic areas does IMMUNE PHARMACEUTICALS INC focus on?
IMMUNE PHARMACEUTICALS INC develops therapies across Oncology, Neurology, Immunology, Pain, Dermatology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.